ФИЗИОЛОГИЧЕСКАЯ СИСТЕМА СОЕДИНИТЕЛЬНОЙ ТКАНИИ ОНКОГЕНЕЗ.III. Формирование резистентностик химиопрепаратам
Ключові слова:
злокачественные опухоли, система соединительной ткани, клетки стромы, экстрацеллюлярный матрикс, резистентность к химиопрепаратам.Анотація
Освещены современные представления о роли компонентов соединительной ткани в формировании резистентности злокачественных опухолей
к химиопрепаратам. Рассмотрены механизмы участия в резистентности опухолеассоциированных фибробластов, звездчатых клеток, адипоцитов, мезенхимальных стволовых клеток, а также некоторых компонентов экстрацеллюлярного матрикса. Представлена информация о роли
микроокружения, гипоксии, экстрацеллюлярных везикул (как опухолевых,
так и стромальных клеток) в формировании резистентности. По мере обсуждения делается акцент на перспективах некоторых подходов к преодолению резистентности с участием компонентов соединительной ткани.
Посилання
Бережная НМ, Чехун ВФ. Физиологическая система соединительной ткани и онкогенез. I. Роль клеточных компонентов стромы в развитии опухоли. Онкология 2016; 18 (1): 4–12.
Бережная НМ, Чехун ВФ. Физиологическая система соединительной ткани и онкогенез. ІІ. Экстрацеллюлярный матрикс и метастазирование. Онкология 2016; 18 (3): 164–76.
Ryner L, Guan Y, Firestein R, et al. Upregulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res 2015; 21 (13): 2941–51.
Park JH, Richards CH, McMillan DC, et al. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 2014; 25 (3): 644–51.
Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012; 19 (6): R187–204.
Sun XJ, Jiang TH, Zhang XP, Mao AW. Role of the tumor microenvironment in pancreatic adenocarcinoma. Front Biosci (Landmark Ed) 2016; 21: 31–41.
Velaei K, Samadi N, Barazvan B, Soleimani Rad J. Tumor microenvironment-mediated chemoresistance in breast cancer. Breast 2016; 30: 92–100.
Cammarota F, Laukkanen MO. Mesenchymal stem/stromal cells in stromal evolution and cancer progression. Stem Cells Int 2016; 2016: 4824573.
Oh SY, Kim H. Molecular culprits generating brain tumor stem cells. Brain Tumor Res Treat 2013; 1 (1): 9–15.
Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013; 85 (8): 1033–41.
Vaupel P, Mayer A, Briest S, Höckel M. Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 2005; 566: 333–42.
Höckel M, Schlenger K, Höckel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59 (18): 4525–8.
Chen J, Ding Z, Peng Y, et al. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One 2014; 9 (6): e98882.
Gilkes DM, Chaturvedi P, Bajpai S, et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. Cancer Res 2013; 73 (11): 3285–96.
Xiang L, Gilkes DM, Hu H, et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce
the breast cancer stem cell phenotype. Oncotarget 2014; 5 (24): 12509–27.
Zhang L, Huang G, Li X, et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1α in hepatocellular carcinoma. BMC Cancer 2013; 13: 108.
Fu P, Du F, Chen W, et al. Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines. Oncol Rep 2014; 31 (6): 2561–8.
Yang SW, Zhang ZG, Hao YX, et al. HIF-1α induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway. Oncotarget 2017; 8 (6): 9535–45.
Velaei K, Samadi N, Soltani S, et al. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC
transporters in breast cancer. Breast Cancer 2017; 24 (4): 552–61.
Kanada M, Bachmann MH, Hardy JW, et al. Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci U S A 2015; 112 (12): E1433–42.
Salem KZ, Moschetta M, Sacco A, et al. Exosomes in tumor angiogenesis. Methods Mol Biol 2016; 1464: 25–34.
Corcoran C, Rani S, O’Brien K, et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012; 7 (12): e50999.
Mao L, Li J, Chen WX, et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol 2016; 37 (4): 5247–56.
Nakano I, Garnier D, Minata M, Rak J. Extracellular vesicles in the biology of brain tumour stem cells — Implications for inter-cellular communication, therapy and biomarker development. Semin Cell Dev Biol 2015; 40: 17–26.
Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med 2016; 14 (1): 297.
Zomer A, Vendrig T, Hopmans ES, et al. Exosomes: Fit to deliver small RNA. Commun Integr Biol 2010; 3 (5): 447–50.
Zöller M. Exosomes in cancer disease. Methods Mol Biol 2016; 1381: 111–49.
Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol 2015; 40: 41–51.
Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 2016; 7: 11150.
Ciardiello C, Cavallini L, Spinelli C, et al. Focus on extracellular vesicles: New frontiers of cell-to-cell communication in
cancer. Int J Mol Sci 2016; 17 (2): 175.
Minciacchi VR, You S, Spinelli C, et al. Large oncosomes contain distinct protein cargo and represent a separate functional class oftumor-derived extracellular vesicles. Oncotarget 2015; 6 (13): 11327–41.
Lunavat TR, Cheng L, Kim DK, et al. Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells. Evidence of unique microRNA cargos. RNA Biol 2015; 12 (8): 810–23.
Tosar JP, Gambaro F, Sanguinetti J, et al. Assessment of small RNA sorting into different extracellular fractions revealed by high-throughput sequencing of breast cell lines. Nucleic Acids Res 2015; 43: 5601–16.
Di Vizio D, Kim J, Hager MH, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69 (13): 5601–9.
Di Vizio D, Morello M, Dudley AC, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012; 181 (5): 1573–84.
Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumabbased therapy. J Cell Physiol 2012; 227 (2): 658–67.
Vargas JR, Stanzl EG, Teng NN, Wender PA. Cell-penetrating, guanidinium-rich molecular transporters for overcoming
efflux-mediated multidrug resistance. Mol Pharm 2014; 11 (8): 2553–65.
Webber J, Steadman R, Mason MD, et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer
Res 2010; 70 (23): 9621–30.
Gu J, Qian H, Shen L, et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS One 2012; 7 (12): e52465.
Webber JP, Spary LK, Sanders AJ, et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2015; 34 (3): 290–302.
Cho JA, Park H, Lim EH, et al. Exosomes from ovaria cancer cells induce adipose tissue-derived mesenchymal stem cellsto acquire the physical and functional characteristics of tumorsupporting myofibroblasts. Gynecol Oncol 2011; 12 (2): 379–86.
Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem ells into myofibroblast-like cells. Int J Oncol 2012; 40 (1): 130–8.
Ekström EJ, Bergenfelz C, von Bülow V, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014; 13: 88.
Takahashi K, Yan IK, Kogure T, et al. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates
chemosensitivity in human hepatocellular cancer. FEBS Open Bio 2014; 4: 458–67.
Ma L, Li Y, Peng J, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res 2015; 25 (1): 24–38.
Luga V, Wrana JL. Tumor-stroma interaction: Revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res 2013; 73 (23): 6843–7.
Bussard KM, Mutkus L, Stumpf K, et al. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 2016; 18 (1): 84.
Ramteke A, Ting H, Agarwal C, et al. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog 2015; 54 (7): 554–65.
Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18 (6): 883–91.
Le MT, Hamar P, Guo C, et al. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest 2014; 124 (12): 5109–28.
Melo SA, Sugimoto H, O’Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014; 26 (5): 707–21.
Shen L, Wan Z, Ma Y, et al. The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers.
Tumour Biol 2015; 36 (3): 1993–2005.
Kalluri R. The biology and function of exosomes in cancer. J Clin Inves 2016; 126 (4): 1208–15.
Wieckowski EU, Visus C, Szajnik M, et al. Tumor-derived microvesicles promote regulatory T cell expansion and in duce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009; 183 (6): 3720–30.
Szajnik M, Czystowska M, Szczepanski MJ, et al. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (treg). PLoS One 2010; 5 (7): e11469.
Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derivedexosomes). Biochem Soc Trans 2013; 41 (1): 245–51.
Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012; 151 (7): 42–56.
Hu Y, Yan C, Mu L, et al. Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer. PLoS One 2015; 10 (5): e0125625.
Boelens MC, Wu TJ, Nabet BY, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014; 159 (3): 499–513.
Fu H, Yang H, Zhang X, Xu W. The emerging roles of exosomes in tumor-stroma interaction. J Cancer Res Clin Oncol 2016; 142 (9): 1897–907.
Huijbers EJ, van Beijnum JR, Thijssen VL, et al. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat 2016; 25: 26–37.
Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med
(Berl) 2013; 91 (4): 431–7.
Whiteside TL. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn 2015; 15 (10): 1293–310.
Malek AV, Bershteǐn LM, Filatov MV, Beliaev AM. Exosomal intercellular communication system and its role in the process of metastatic dissemination. Vopr Onkol 2014; 60 (4): 429–36 (in Russian).
Wu J, Qu Z, Fei ZW, et al. Role of stem cell-derived exosomes in cancer. Oncol Lett 2017; 13 (5): 2855–66.
Zhang X, Yuan X, Shi H, et al. Exosomes in cancer: small particle, big player. J Hematol Oncol 2015; 8: 83.
Wendler F, Favicchio R, Simon T, et al. Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention. Oncogene 2017; 36 (7): 877–84.
Wang Z, Chen JQ, Liu JL, Tian L. Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med 2016; 14 (1): 297.
Бережная Н.М. Семейства интерлейкинов: биология и онкогенез. Киев: Наукова думка, 2013. 575 с.
Wang T, Jiang CX, Li Y, Liu X. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Zhonghua Bing Li Xue Za Zhi 2009; 38 (12): 824–8.
Kim HM, Lee YK, Koo JS. Expression of CAF-Related proteins is associated with histologic grade of breast phyllodes tumor. Dis Markers 2016; 2016: 4218989.
Kharaishvili G, Simkova D, Bouchalova K, et al. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell International 2014; 14 (1, article no. 41).
Kim HM, Jung WH, Koo JS. Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis. J Transl Med 2015; 13: 222.
Park SY, Kim HM, Koo JS. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 2015; 149 (3): 727–41.
Erez N, Glanz S, Raz Y, et al. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun 2013; 437 (3): 397–402.
Duluc C, Moatassim-Billah S, Chalabi-Dchar M, et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med 2015; 7 (6): 735–53.
Tanaka K, Miyata H, Sugimura K, et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis 2015; 36 (8): 894–903.
Peiris-Pagès M, Smith DL, Győrffy B, et al. Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts. Aging (Albany NY) 2015; 7 (10): 816–38.
Deying W, Feng G,Shumei L, et al. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the
c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep 2017; 37 (2): pii: BSR20160470.
von Ahrens D, Bhagat TD, Nagrath D, et al. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol 2017; 10 (1): 76.
Dai M, Al-Odaini AA, Arakelian A, et al. A novel function
for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res 2012; 14 (5): R127.
Kim IY, Jeong S, Kim ES, et al. Type I collagen-induced pro-MMP-2 activation is differentially regulated by H-Ras and N-Ras in human breast epithelial cells. J Biochem Mol Biol 2007; 40 (5): 825–31.
Wang W, Li Q, Yamada T, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009; 15 (21): 6630–8.
Kunita A, Kashima TG, Morishita Y, et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007; 170 (4): 1337–47.
Takahashi A, Ishii G, Neri S, et al. Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth. Oncotarget 2015; 6 (11): 9531–41.
Hoshino A, Ishii G, Ito T, et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 2011; 71: 4769–79.
Yoshida T, Ishii G, Goto K, et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res 2015; 21 (3): 642–51.
Shan T, Chen S, Chen X, et al. Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism. Oncol Rep 2017; 37 (4): 1971–79.
Shan T, Chen S, Chen X, et al. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Int J Oncol 2017; 50 (1): 121–8.
Pietilä M, Ivaska J, Mani SA. Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment? Cancer Lett 2016; 380 (1): 359–68.
Deep G, Panigrahi GK. Hypoxia-induced signaling promotes prostate cancer progression: exosomes role as messenger of hypoxic response in tumor microenvironment. Crit Rev Oncog 2015; 20 (5–6): 419–34.
Kadera BE, Li L, Toste PA, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 2013; 8 (8): e71978.
Shah SH, Miller P, Garcia-Contreras M, et al. Hierarchical paracrine interaction of breast cancer associated fibroblasts
with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype. Cancer Biol Ther 2015; 16 (11): 1671–81.
Han SH, Kim HJ, Gwak JM, et al. MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer. J Breast Cancer 2017; 20 (1): 35–44.
Taddei ML, Cavallini L, Comito G, et al. Senescent stroma promotes prostate cancer progression: the role of miR-210. Mol Oncol 2014; 8 (8): 1729–46.
Schmitz S, Rommel D, Michoux N, et al. Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. Radiol Oncol 2015; 49 (1): 17–25.
Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007; 170 (5): 1546–60.
Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014; 32 (1): 145–56.
Han Y, Zhang Y, Jia T, Sun Y. Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts. Tumour Biol 2015; 36 (3): 1385–94.
Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med 2016; 14: 21.
Liu Z, Xu J, He J, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 2015; 6 (33): 34329–41.
Duong MN, Cleret A, Matera EL, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res 2015; 17: 57.
Nieman KM, Romero IL, Van Houten B, Lengye E. Adipose tissue and adipocytes supports tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831 (10): 1533–41.
Tagliabue E, Campiglio M, Pupa SM, et al. Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 2012; 38 (3): 212–7.
Yu G, Jing Y, Kou X, et al. Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One 2013; 8 (9): e73312.
Wen-Ting Liu, Ying-Ying Jing, Guo-feng Yu, et al. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/
c-Met signaling pathway regulated by p53. Cell Cycle 2016; 15 (7): 886–94.
Chen W, Wu J, Shi H, et al. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/ Akt and Jak2/Stat3 pathways. Biomed Res Int 2014; 2014: 764981.
Xu Z, Pothula SP, Wilson JS, Apte MV. Pancreatic cancer and its stroma: A conspiracy theory. World J Gastroenterol 2014; 20 (32): 11216–29.
Wilson JS, Pirola RC, Apte MV. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Front Physiol 2014; 5: 52.
Liu Y, Li F, Gao F, et al. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Tumour Biol 2016; 37 (11): 15283–91.
Zhang L, Li Y, Qiao L, et al. Protective effects of hepatic stellate cells against cisplatin-induced apoptosis in human hepatoma G2 cells. Int J Oncol 2015; 47 (2): 632–40.
Coffman LG, Choi YJ, McLean K, et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 2016; 7 (6): 6916–32.
Ren G, Liu Y, Zhao X, et al. Tumor resident mesenchymal stromal cells endow naïve stromal cells with tumor-promoting properties. Oncogene 2014; 33 (30): 4016–20.
Liu R, Wei S, Chen J, Xu S. Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer letters 2014; 353 (2): 145–52.
Santamaria-Martínez A, Barquinero J, Barbosa-Desongles A, et al. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Exp Cell Res 2009; 315 (17): 3004–13.
Klopp AH, Spaeth EL, Dembinski JL, et al. Tumor irradiation increases the recruitment of circulating mesenchymal
stem cells into the tumor microenvironment. Cancer Res 2007; 67 (24): 11687–95.
Shi Y, Xia YY, Wang L, et al. Neural cell adhesion molecule modulates mesenchymal stromal cell migration via activation of MAPK/ERK signaling. Exp Cell Res 2012; 318 (17): 2257–67.
Lin SY, Dolfi SC, Amiri S, et al. P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms. Int J Oncol 2013; 43 (6): 1817–23.
McAndrews KM, McGrail DJ, Ravikumar N, Dawson MR. Mesenchymal stem cells induce directional migration of invasive breast cancer cells through tgf-β. Sci Rep 2015; 5: 16941.
Bayo J, Fiore E, Aquino JB, et al. Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma. PLoS One 2014; 9 (4): e95171.
Dostert G, Mesure B, Menu P, Velot É. How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? Front Cell Dev Biol 2017; 5: 6.
Ji R, Zhang B, Zhang X, et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle 2015; 14 (15): 2473–83.
Kucerova L, Zmajkovic J, Toro L, Skolekova S, et al. Tumor-driven molecular changes in human mesenchymal stromal
cells. Cancer Microenviron 2015; 8 (1): 1–14.
Otte A, Yang Y, von der Ohe J, et al. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment. Int J Oncol 2016; 49 (6): 2453–63.
Tu B, Peng ZX, Fan QM, et al. Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal
stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Re. 2014; 320 (1): 164–73.
Corallini F, Secchiero P, Beltrami AP, et al. TNF-alpha
modulates the migratory response of mesenchymal stem cells to TRAIL. Cell Mol Life Sci 2010; 67 (8): 1.
Eterno V, Zambelli A, Pavesi L, et al. Adipose-derived mesenchymal stem cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget 2014; 5 (3): 613–33.
Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36 (10): 2566–73.
Chiesa S, Morbelli S, Morando S, et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A 2011; 108 (42): 17384–9.
Giallongo C, Romano A, Parrinello NL, et al. Mesenchymal stem cells (msc) regulate activation of granulocyte-like myeloid derived suppressor cells (g-mdsc) in chronic myeloid leukemia patients. PLoS One 2016; 11 (7): e0158392.
Xia B, Tian C, Guo S, et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res 2015; 39 (1): 92–9.
Langroudi L, Hassan ZM, Soleimani M, Hashemi SM. Tumor associated mesenchymal stromal cells show higher immunosuppressive and angiogenic properties compared to adipose derived mscs. Iran J Immunol 2015; 12 (4): 226–39.
Sofeu Feugaing DD, Götte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol
; 92 (1): 1–11.
Liotta LA. Adhere, degrade, and move: the three-step model of invasion. Cancer Res 2016; 76 (11): 3115–7.
Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep 2014; 15 (12): 1243–53.
Kaushik S, Pickup MW, Weaver VM. From transformation to metastasis: deconstructing the extracellular matrix in breast cancer. Cancer Metastasis Rev 2016; 35 (4): 655–67.
Tung JC, Barnes JM, Desai SR, et al. Tumor mechanics and metabolic dysfunction. Free Radic Biol Med 2015; 79: 269–80.
Wang K, Seo BR, Fischbach C, Gourdon D. Fibronectin mechanobiology regulates tumorigenesis. Cell Mol Bioeng
; 9: 1–11.
Cho C, Horzempa C, Jones D, McKeown-Longo PJ. The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells. BMC Cancer 2016; 16: 574.
Wang W, Ma JL, Jia WD, Xu GL. Periostin: a putative
mediator involved in tumour resistance to anti-angiogenic therapy? Cell Biol Int 2011; 35 (11): 1085–8.
Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013; 62 (1): 112–20.
Torre C, Wang SJ, Xia W, Bourguignon LY. Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck Surg 2010; 13 (5): 493–501.
Chen PC, Cheng HC, Yang SF, et al. The CCN family proteins: modulators of bone development and novel targets in boneassociated tumors. Biomed Res Int 2014; 2014: 437096.
Kubota S, Takigawa M. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions. Clin Sci (Lond); 128 (3): 181–96.
Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004; 279 (23): 24015–23.
Kaylan KB, Gentile SD, Milling LE, et al. Mapping lung tumor cell drug responses as a function of matrix context and genotype using cell microarrays. Integr Biol (Camb) 2016; 8 (12): 1221–31.
Tumbarello DA, Temple J, Brenton JD. β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol Cancer 2012; 11: 36.
Kontsekova S, Polcicova K, Takacova M, Pastorekova S. Endosialin: molecular and functional links to tumor angiogenesis. Neoplasma 2016; 63 (2): 183–92.
Craft CS, Pietka TA, Schappe T, et al. The extracellular matrix protein MAGP1 supports thermogenesis and protects
against obesity and diabetes through regulation of TGF-β. Diabetes 2014; 63 (6): 1920–32.
Midgley AC, Rogers M, Hallett MB, et al. Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem 2013; 288: 14824–38.
Berezhnaya NM, Kovalchuk WV, Spivak UD, et al. Antitumor activity of lymphocytes upon the development of the resistance to doxorubicine in MCA-rhabdomyosarcoma-bearing mice. Exp Oncol 2002; 24: 292–4.
Berezhnaya NM, Vinnichuk UD, Konovalenko VF, et al. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: a pilot study. Exp Oncol 2005; 27 (4): 303–7.
